Novartis backs Gamida Cell’s $40M raise to fund a looming PhIII study, marketing and manufacturing prep
Israel’s Gamida Cell now has the cash it needs to execute on a late-stage trial for its experimental cell graft, which it hopes can be OK’d for use when the right bone marrow donor can’t be found for patients suffering from leukemia and lymphoma.
Longtime backer Novartis jumped back in on this raise, joining lead investor Shavit Capital along with new investors VMS Investment Group and Israel Biotech Fund and current investors Clal Biotechnology Industries and Israel HealthCare Ventures.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.